Southern California Desert Retina Consultants, MC   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Palm Desert CA United States

Organization Overview

First Clinical Trial
2008
NCT00749021
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Clement K. Chan | Southern California Desert Retina Consultants | Southern California Desert Retina Consultants, MC

Active Ingredients

Drugs in Phase 4 Trials (1)

aflibercept (zaltrap) (1 trial)

Drugs in Phase 2 Trials (1)

ranibizumab (lucentis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroidal Neovascularization (Phase 1)

Dissociative Disorders (Phase 4)

Macular Degeneration (Phase 2)

Retinal Detachment (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 2